Acetylon Pharmaceuticals Announces Issuance of a United States Patent with Composition of Matter Claims for Its Lead HDAC6 Inhibitor Drug Candidate ACY-1215

Published: Apr 20, 2012

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc. today announced that it has been granted U.S. Patent 8,148,526 by the United States Patent and Trademark Office (USPTO). This patent contains fundamental composition of matter claims covering the Company’s selective HDAC6 inhibitor, ACY-1215TM, which is currently being investigated in human clinical trials for the treatment of multiple myeloma. Acetylon also announced that Chief Executive Officer, Walter Ogier, will present an overview of the Company at 1:30 PM today at the 19th Annual Future Leaders in the Biotech Industry Conference, hosted by BioCentury and Thomson Reuters at the Millennium Broadway Hotel & Conference Center in New York City.

Back to news